Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,722 shares of the pharmaceutical company’s stock after buying an additional 48 shares during the period. Avior Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,108,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals during the third quarter worth about $25,000. Arlington Trust Co LLC raised its holdings in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares in the last quarter. Compass Wealth Management LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $29,000. Fortitude Family Office LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Finally, Baystate Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VRTX. Royal Bank of Canada increased their price target on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 6th. Barclays increased their target price on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Evercore ISI raised shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price for the company in a report on Thursday, April 11th. Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Truist Financial increased their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $424.62.

Vertex Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ VRTX opened at $393.10 on Thursday. Vertex Pharmaceuticals Incorporated has a 1 year low of $316.43 and a 1 year high of $448.40. The firm’s 50 day moving average price is $414.76 and its 200 day moving average price is $396.76. The firm has a market cap of $101.60 billion, a P/E ratio of 28.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the business earned $3.33 earnings per share. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.